Abstract
Alefacept is the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. It is a fully human fusion toxin, which binds to CD2, blocks costimulatory signaling, and selectively induces apoptosis of activated memory T cells involved in the pathogenesis of psoriasis. Alefacept has a slow onset of action, peaking approximately 18 weeks after the first injection of a 12-week course. However, it has several important advantages over the existing conventional immunosuppressive therapies for psoriasis: it is associated with long remissions without the need for maintenance therapy; its efficacy improves with subsequent courses; and it has a high safety profile. This review summarizes the mechanism of action of alefacept and the results of the clinical trials, with special emphasis on efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability. Current guidelines based on the best available data to date are also presented.
References
Jan 1, 1989·Archives of Dermatological Research·J D BosM L Kapsenberg
Dec 1, 1995·The Journal of Investigative Dermatology·E W JeffesS Edwards
May 1, 1995·Nature Medicine·S L GottliebJ G Krueger
Jul 1, 1993·The Journal of Experimental Medicine·G T MillerB P Wallner
Feb 1, 1995·The Journal of Investigative Dermatology·E W JeffesA Schlotzhauer
Feb 15, 1996·Transplantation·R J KaplonC C Marboe
May 1, 1996·Photochemistry and Photobiology·R JohnsonJ G Krueger
Feb 17, 1999·The Journal of Experimental Medicine·M OzawaJ G Krueger
Jul 20, 1999·Journal of the American Academy of Dermatology·J Koo, M Lebwohl
Jan 6, 2001·Archives of Dermatological Research·M FriedrichK Asadullah
Jul 14, 2001·Journal of the European Academy of Dermatology and Venereology : JEADV·P CarliB Giannotti
Jul 28, 2001·The New England Journal of Medicine·C N EllisUNKNOWN Alefacept Clinical Study Group
Oct 9, 2001·Lancet·I Marcil, R S Stern
Nov 13, 2001·Clinical and Experimental Immunology·H SigmundsdóttirH Valdimarsson
Nov 27, 2002·Journal of the American Academy of Dermatology·Gerald G KruegerUNKNOWN Alefacept Clinical Study Group
Mar 26, 2003·International Journal of Dermatology·Nick J LoweAlan Menter
May 20, 2003·The British Journal of Dermatology·G G Krueger, C N Ellis
Jun 11, 2003·Journal of the European Academy of Dermatology and Venereology : JEADV·J-P Ortonne
Jun 18, 2003·Archives of Dermatology·Mark LebwohlUNKNOWN Alefacept Clinical Study Group
Aug 2, 2003·Journal of the American Academy of Dermatology·Gerald G Krueger, Kristina P Callis
Sep 10, 2003·Journal of the American Academy of Dermatology·Emmilia HodakMichael David
Oct 25, 2003·Journal of the American Academy of Dermatology·Alice B GottliebKenneth B Gordon
Oct 25, 2003·Journal of the American Academy of Dermatology·Jeffrey P CallenUNKNOWN AAD
Dec 17, 2003·Archives of Dermatology·Kenneth B GordonUNKNOWN Alefacept Clinical Study Group
Jun 21, 2005·Journal of the American Academy of Dermatology·Carin H GribetzMark Lebwohl
Citations
Jan 18, 2015·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Ulrike ErbenAnja A Kühl
Oct 23, 2009·Dermatologic Therapy·Eihab A AlwawiKenneth B Gordon
Apr 9, 2008·Dermatologic Therapy·Julia Tzu, Francisco Kerdel
May 31, 2008·The Journal of Dermatological Treatment·David CarrSteven R Feldman
Jan 22, 2008·Actas dermo-sifiliográficas·G GuhlJ Fernández-Herrera